CN111529150A - Sinus duct stent and preparation method thereof - Google Patents

Sinus duct stent and preparation method thereof Download PDF

Info

Publication number
CN111529150A
CN111529150A CN202010353321.5A CN202010353321A CN111529150A CN 111529150 A CN111529150 A CN 111529150A CN 202010353321 A CN202010353321 A CN 202010353321A CN 111529150 A CN111529150 A CN 111529150A
Authority
CN
China
Prior art keywords
stent
sinus
hollow
drug
support
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202010353321.5A
Other languages
Chinese (zh)
Other versions
CN111529150B (en
Inventor
白晶
王先丽
程兆俊
邵怡
薛烽
储成林
汪丰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Southeast University Suzhou Medical Device Research Institute
Original Assignee
Southeast University Suzhou Medical Device Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Southeast University Suzhou Medical Device Research Institute filed Critical Southeast University Suzhou Medical Device Research Institute
Priority to CN202010353321.5A priority Critical patent/CN111529150B/en
Publication of CN111529150A publication Critical patent/CN111529150A/en
Application granted granted Critical
Publication of CN111529150B publication Critical patent/CN111529150B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/82Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/86Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
    • A61F2/90Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B33ADDITIVE MANUFACTURING TECHNOLOGY
    • B33YADDITIVE MANUFACTURING, i.e. MANUFACTURING OF THREE-DIMENSIONAL [3-D] OBJECTS BY ADDITIVE DEPOSITION, ADDITIVE AGGLOMERATION OR ADDITIVE LAYERING, e.g. BY 3-D PRINTING, STEREOLITHOGRAPHY OR SELECTIVE LASER SINTERING
    • B33Y70/00Materials specially adapted for additive manufacturing
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B33ADDITIVE MANUFACTURING TECHNOLOGY
    • B33YADDITIVE MANUFACTURING, i.e. MANUFACTURING OF THREE-DIMENSIONAL [3-D] OBJECTS BY ADDITIVE DEPOSITION, ADDITIVE AGGLOMERATION OR ADDITIVE LAYERING, e.g. BY 3-D PRINTING, STEREOLITHOGRAPHY OR SELECTIVE LASER SINTERING
    • B33Y80/00Products made by additive manufacturing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2210/00Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2210/0004Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof bioabsorbable
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2210/00Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2210/0014Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof using shape memory or superelastic materials, e.g. nitinol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2240/00Manufacturing or designing of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2240/001Designing or manufacturing processes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2310/00Prostheses classified in A61F2/28 or A61F2/30 - A61F2/44 being constructed from or coated with a particular material
    • A61F2310/00389The prosthesis being coated or covered with a particular material
    • A61F2310/0097Coating or prosthesis-covering structure made of pharmaceutical products, e.g. antibiotics

Landscapes

  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Manufacturing & Machinery (AREA)
  • Materials Engineering (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Media Introduction/Drainage Providing Device (AREA)

Abstract

The invention provides a sinus duct stent and a preparation method thereof. The preparation method comprises the following steps: providing a preset thermoplastic degradable polymer, printing the thermoplastic degradable polymer into a slice on an XOY plane by adopting a 3D printing technology, curling the slice into an annular structure around a preset reference axis, performing heat treatment setting on the annular structure after the slice is pre-fixed to obtain a hollow stent, forming a porous drug carrying layer on the surface of the hollow stent, and performing hole sealing treatment on the porous drug carrying layer to obtain the sinus duct stent. The preparation method provided by the invention is not limited by the precision of a fused deposition type 3D printer instrument, ensures the consistency of the forming conditions of each part of the stent, so that the stent has good elasticity, can effectively prevent the stent from escaping from a matrix and subsequent sudden release of the drug in the deployment process, and simultaneously avoids the problem of insufficient drug loading capacity, thereby achieving the purpose of preventing the occurrence of medical accidents such as secondary blockage caused by the proliferation of the nasal cavity granulation tissue into the nasal cavity space.

Description

Sinus duct stent and preparation method thereof
Technical Field
The invention belongs to the technical field of biomedical equipment, and particularly relates to a sinus duct stent and a preparation method thereof.
Background
Human nasal obstruction is a common disease in clinic. It often causes the patient to breathe unsmoothly, even causes facial deformity and paralysis, and directly influences the normal life of people. The main method of the current interventional therapy is to send an elution stent with a drug on the surface into a blocked nasal cavity part by using a catheter delivery system, so that the narrow nasal cavity is expanded and the repair function can be achieved by using the drug effect.
The defects of the existing bracket preparation technology are as follows: the requirements of nasal cavities of different individuals on the size of the bracket are different, the bracket prepared by the traditional method has low efficiency, poor repeatability and difficulty in timely adjustment of the size, the bracket with the hollowed side surface prepared by the laser engraving method has high cost and the wall thickness is not easy to control. With the rise of 3D printing technology, the modern molding technology with low cost, no raw material waste, high efficiency and good repeatability is widely applied to the preparation of medical instruments. For the preparation of tubular stents, the following disadvantages exist with the conventional Z-direction stacking technique: (1) the preparation of the bracket with small diameter and a complex pattern structure on the surface is difficult to realize due to the limitation of instrument precision; (2) the support prepared by stacking in the Z-axis direction needs to be thick in wall thickness, otherwise, the requirement of high vertical stacking height is difficult to realize; (3) the limitation of the wall thickness causes that the high polymer material stent prepared by stacking in the Z-axis direction in 3D printing is hard and brittle and has almost no self-expansion performance.
The 3D that product performance is better prints support is prepared out to china patent CN 102149859B of one of prior art at present, and its support adopts the support that 3D 4 axle rapid prototyping system prepared, and the support of printing can satisfy the requirement of self-expanding performance, but has higher requirement to 3D printer precision and type, and the diameter of support changes difficultly, and the improvement of equipment cost is not as much as having increased the whole cost of sinus pipe support. In addition, although the ultraviolet light curing molding (SLA) combined Continuous Liquid Interface Production (CLIP) technology adopted in the above patent can realize the preparation of the ultrafine vascular stent, the method requires the use of precise instruments. In addition, the rapid curing of the photosensitive resin by ultraviolet light-initiated photopolymerization requires the addition of potentially toxic chemical agents such as photoinitiators to the printing ink. In addition, the SLA raw material is photosensitive resin, when a body-type structure is formed to achieve the purpose of curing, the degradation mechanism of the cured resin material applied to the human body is no longer the bond breaking mechanism of a linear polymer material, the degradation mechanism is the typical water absorption and swelling mechanism of a body-type high polymer material, and the risk of inducing potential safety hazard after the SLA raw material is implanted into the human body exists, so that the preparation method has no universality.
The 3D printing technology is well known for its high efficiency, and fused deposition type 3D printers require that polymer is sprayed from a nozzle and deposited on a hot bed, and then rapidly cooled and solidified to enable the next layer to be stacked. For semi-crystalline polymeric materials, the degree of crystallinity depends on how fast the sample is going to melt and cool. When the polymer material is cooled at a fast rate in the 3D printing rapid forming process, the prepared stent product often has the problems of high brittleness and the like.
The high polymer material has viscosity after reaching the melting point temperature, and can play a role in bonding two adjacent matrixes, but for the support, after two welding edges are simply welded, the support can generate stress concentration when stressed, and the welding edges can be firstly broken to cause the support to lose efficacy and not play a supporting role; the general polymer material is a hydrophobic material, and has weak binding capacity with the drug, so that the drug is difficult to bind with the stent main body, the drug is often released suddenly, the therapeutic purpose cannot be achieved, and the drug poisoning of a patient can be caused.
The balloon method adopted in the existing stent deployment scheme can cause huge mechanical destructive damage to the lumen, and risks of scratching and even breaking the lumen wall exist. In particular, during deployment of a polymer-based luminal stent, the stent can undergo a severe plastic deformation process; in this case, if the drug is carried on the surface of the stent, the drug coating is likely to fall off, and thus the total drug dose may be insufficient after the stent is implanted into the lesion of the human body, and it is difficult to ensure the therapeutic effect of the interventional stent.
For the reasons, the preparation method of the bracket customized according to different human nasal cavity environments is worthy of being researched by medical workers. The support wall that 3D printed method was made is too thick and inelastic in Z axle direction stacking, tubular 3D printed method requires too high and difficult acquisition to instrument itself, and increased the cost of support, the support that the photocuring was printed possesses very big medical risk because of the restriction of raw materials is implanted in the human body, and, the degradation cycle and the tissue healing cycle of support are asynchronous, the welding limit that hot gas welding caused is cracked by stress concentration, key technical problems such as speed and the dose control of medicine release need to be solved urgently.
Disclosure of Invention
The invention aims to at least solve one of the technical problems in the prior art and provides a sinus duct stent and a preparation method thereof.
The invention provides a preparation method of a sinus duct stent, which comprises the following specific steps:
providing a preset thermoplastic degradable polymer, and printing the thermoplastic degradable polymer into a thin sheet on an XOY plane by adopting a 3D printing technology;
coiling the thin slice around a preset reference shaft to form an annular structure, and after the thin slice is pre-fixed, carrying out heat treatment setting on the annular structure to obtain a hollow support;
forming a porous drug-carrying layer on the surface of the hollow stent;
and carrying out hole sealing treatment on the porous medicine carrying layer to obtain the sinus duct stent.
Optionally, after the pre-fixing, performing heat treatment setting on the annular structure to obtain the hollow support includes:
carrying out heat treatment setting on the annular structure at 40-50 ℃ for 2-5 min to obtain a semi-finished hollow bracket;
and preparing and forming a reinforcing rib on the semi-finished hollow support to obtain the hollow support.
Optionally, the preparing and forming a reinforcing rib on the semi-finished hollow support to obtain the hollow support includes:
and melting the welding areas on the two sides of the semi-finished hollow support, applying welding pressure to form a spiral reinforcing rib wound on the outer surface of the semi-finished hollow support, and annealing at 40-50 ℃ for 5-20 min to obtain the hollow support.
Optionally, the forming a porous drug-carrying layer on the surface of the hollow stent includes:
immersing the hollow stent into 80-120 mL of mixed solution of drug and chitosan, ultrasonically immersing for 0.5-1.5 h, and then carrying out freeze drying treatment to enable the chitosan to crust on the surface of the hollow stent to form the porous drug carrying layer.
Optionally, the drug-chitosan mixed solution comprises acetic acid with a concentration range of 1% (v/v) to 3% (v/v), chitosan with a viscosity range of 400mPa · s to 600mPa · s, a concentration range of 1% (w/v) to 3% (w/v), and sirolimus drug; wherein the content of the first and second substances,
the sirolimus drug loading amount accounts for 10% (w/w) to 20% (w/w) of the total amount of the chitosan.
Optionally, the hole sealing treatment is performed on the porous drug carrying layer to obtain the sinus duct stent, including:
immersing the hollow stent with the porous drug-carrying layer into 80-120 mL of sodium alginate saturated aqueous solution, and dropwise adding the solution into 80-120 mL of CaCl2Mechanically stirring the solution for 5 to 15min to form calcium alginate hydrogel;
and sealing the porous drug-carrying layer by using the calcium alginate hydrogel, and carrying out freeze drying treatment to obtain the sinus duct stent.
Optionally, the thermoplastic degradable polymer comprises at least one of polylactic acid, polycaprolactone, polyglycolic acid, polylactic-glycolic acid.
Optionally, the sheet is a parallelogram sheet; wherein the content of the first and second substances,
the parallelogram thin slice is provided with any one of rhombus patterns, triangle patterns, trapezoid patterns and circular patterns which penetrate through the thickness of the parallelogram thin slice.
Optionally, the length range of the sheet is 10 mm-20 mm, the width range is 20 mm-30 mm, and the thickness range is 0.1mm-0.5 mm.
In a second aspect of the present invention, there is provided a sinus duct support, which is prepared by the above-mentioned sinus duct support preparation method.
The invention provides a preparation method of a sinus duct stent, which comprises the following steps: the method is characterized in that a preset thermoplastic degradable polymer is provided, the thermoplastic degradable polymer is printed out of a sheet on an XOY plane by adopting a 3D printing technology, and compared with a Z-axis direction stacking printing method, the sheet (equivalent to the side structure of the stent) printed on the XOY plane can be used for preparing the sinus duct stent with a small diameter and a wall thickness of 0.1-0.5 mm without the limitation of the precision of a fused deposition type 3D printer instrument, so that the consistency of the molding condition of each part of the stent is ensured, and the stent has good elasticity. And then, curling the formed slices around a preset reference shaft into a ring structure, pre-fixing, carrying out heat treatment setting on the ring structure to obtain a hollow stent, forming a porous drug carrying layer on the surface of the hollow stent, and then carrying out hole sealing treatment on the porous drug carrying layer to obtain the sinus duct stent. The medicine carrying layer formed in the embodiment increases the binding force between the medicine and the stent through hole sealing treatment, so that the medicine layer cannot fall off, the stent is effectively prevented from escaping from a matrix and subsequent sudden release of the medicine in the deployment process, and the problem of insufficient medicine carrying capacity is avoided, so that the probability of occurrence of medical accidents such as secondary blockage caused by the fact that the nasal cavity granulation tissue grows into the nasal cavity space is prevented.
Drawings
FIG. 1 is a flow chart of a method of preparing a sinus duct support according to a first embodiment of the present invention;
FIG. 2 is a side view of a sinus canal stent in accordance with a second embodiment of the present invention in a geometric configuration with lateral expansion of the ribs;
FIG. 3 is a schematic view of the curling direction and the welding edges of a sinus canal stent according to a third embodiment of the present invention;
FIG. 4 is a perspective view and a top view of a sinus duct support according to a fourth embodiment of the present invention;
FIG. 5 is a graph of simulated force analysis of a stent having vertical and helical weld beads according to a fifth embodiment of the present invention;
FIGS. 5(a) and 5(b) are force clouds of a stent with vertical welded edges under simulated nasal cavity wall pressure;
FIGS. 5(c) and 5(d) are respectively a deformed cloud image of a stent with a spiral welding edge under simulation of nasal cavity wall pressure;
FIG. 6 is a scanning electron micrograph of a porous drug-bearing layer formed after dipping and freeze-drying a sinus duct stent according to a sixth embodiment of the present invention;
FIG. 7 is a radial compression-rebound graph of a sinus canal stent having an inner diameter of 6mm and varying wall thickness according to a seventh embodiment of the present invention.
Detailed Description
In order to make the technical solutions of the present invention better understood, the present invention will be described in further detail with reference to the accompanying drawings and specific embodiments.
As shown in fig. 1, in a first aspect of the present invention, a method S100 for preparing a sinus canal stent is provided, which specifically includes the following steps S110 to S140:
and S110, providing a preset thermoplastic degradable polymer, and printing the thermoplastic degradable polymer into a sheet on an XOY plane by adopting a 3D printing technology.
Aiming at the problem that the diameter of the support prepared by the current 3D printing is not easy to change, and the wall thickness of the printed support is too thick and inelastic, the embodiment adopts a fused deposition type 3D printer to print the thermoplastic degradable polymer into a thin slice on an XOY plane, and the thin slice has a thin wall thickness and controllable diameter. Illustratively, and as shown in conjunction with FIG. 2, this embodiment provides the sheet as a parallelogram-shaped sheet having a length in the range of 10mm to 20mm, a width in the range of 20mm to 30mm, and a thickness in the range of 0.1mm to 0.5 mm. That is, the thermoplastic degradable polymer is printed out by a 3D printer into a sheet model of a parallelogram structure, which corresponds to a side-deployed structure of the stent.
Further, the parallelogram sheet of the present embodiment may be a sheet of a side-unfolding model with patterns, that is, any one of a rhombus pattern, a triangle pattern, a trapezoid pattern and a circle pattern penetrating the thickness of the sheet is provided on the sheet, and as an example, as shown in fig. 2, the parallelogram sheet of the present embodiment is provided with a rhombus hollow pattern, but of course, patterns with other shapes may be selected, and this is not particularly limited.
The printing material of the present example is a thermoplastic degradable polymer containing at least one of polylactic acid, polycaprolactone, polyglycolic acid, and polylactic-glycolic acid. That is, any thermoplastic degradable polymer such as polylactic acid, polycaprolactone, polyglycolic acid, and polylactic-glycolic acid may be used as the thermoplastic degradable polymer, or a mixture of these may be used, and of course, other thermoplastic degradable polymers may be used, and they are not particularly limited.
The fused deposition type 3D printing rapid prototyping technology is adopted in the embodiment, the working efficiency is high, the repeatability is high, the manufacturing cost is greatly reduced, the sinus duct support with the small diameter and the wall thickness of 0.1mm-0.5mm can be prepared by printing the side structure of the support on the XOY plane, the limitation of the precision of a fused deposition type 3D printer instrument is avoided, the consistency of the forming condition of each part of the support is ensured, and the support of the embodiment has good elasticity.
And S120, curling the sheet printed in the step S110 into a ring-shaped structure around a preset reference shaft, and performing heat treatment setting on the ring-shaped structure after pre-fixing to obtain the hollow bracket.
It should be noted that the method of winding the sheet into the ring-shaped structure is not limited in this example, and for example, a metal rod may be provided, and the sheet may be wound around the metal rod to form the ring-shaped structure, and of course, the metal rod may be taken out after the ring-shaped structure is formed to obtain the hollow stent, and the size of the metal rod may be specifically selected according to the diameter of the hollow stent, and a copper rod having a diameter in a range of 3mm to 6mm is used in this example.
It should be further noted that the reference axis is not specifically limited in this embodiment, and for example, as shown in fig. 2, a line (004) in fig. 2 is a reference axis (a secondary inversion axis), (005) and (005 ') and (006') are coincident points of a top end and a bottom end of the welding-formed parallelogram side sheet structure, (002) is a skeleton portion of the stent mesh structure, and (003) is a hot-air welding edge. In the embodiment, as shown in fig. 3, the line (004) of the parallelogram sheet is taken as a central axis to be curled, after hot gas welding forming, the top end point (005) is overlapped with the point (005 '), the bottom end point (006) is overlapped with the point (006'), and the corresponding two side edges (003) are taken as welding areas, and after welding, the integrated hollow stent is formed, and the formed hot gas welding edge is spiral.
Specifically, step S120 of this embodiment specifically includes: and (3) coiling the parallelogram thin sheet around a copper rod for a circle according to a reference shaft (004), pre-fixing two ends and the middle area of the thin sheet by using thin copper wires to form a ring structure, and then putting the ring structure into a vacuum drying oven at the temperature of 40-50 ℃ for heat treatment and shaping for 2-5 min to form the hollow support. The hollow support can be specifically set according to actual needs, namely, the diameter of the hollow support can be changed by selecting copper rods with different diameters, the diameter of the support is easy to change, and the method is low in cost.
This embodiment is printed prefabricated support side expansion structure with 3D and is combined with hot gas welding's technique, can prepare out the support of different diameters and wall thickness scope to satisfy the individual demand to support size, radial holding power, elasticity and compliance of different patients, and, the radial holding power and the accessible support wall thickness adjustment of rebound rate of this support.
Furthermore, in order to avoid stress concentration of the bracket when the bracket is stressed after the two welding edges are welded, the welding edges are firstly broken to cause the failure of the bracket and fail to play a supporting role, the embodiment forms the reinforcing ribs in the welding areas so as to obtain the integrated hollow bracket.
Specifically, referring to fig. 4, after the annular structure is heat-treated and shaped at 40-50 ℃ for 2-5 min, the method further comprises preparing and forming a reinforcing rib (001) on the hollow support to obtain an integrated hollow support, wherein the cross section of the integrated hollow support is a hollow cylinder. As shown in fig. 2 and fig. 3, the steps specifically include: and melting the welding areas (003) at the two sides of the semi-finished hollow bracket after heat treatment and shaping, applying welding pressure to the welding areas (003) to form a spiral reinforcing rib (001) wound on the outer surface of the semi-finished hollow bracket, and then annealing at 40-50 ℃ for 5-20 min to obtain the hollow bracket.
In this embodiment, since the reinforcing ribs are further formed in the welding region of the bracket, it is necessary to take out the copper bar after forming the integral hollow bracket having the reinforcing ribs.
This embodiment has not only realized applying welding pressure to the welding area through forming the strengthening rib and has reached the purpose that the welding is tight real, has still guaranteed the radial elasticity of support through forming the spiral strengthening rib, has guaranteed simultaneously that the support is unlikely to early fracture and inefficacy when receiving nasal cavity wall pressure grip, thereby prevent effectively that the support position of fracture department in advance from causing great block to drop and leading to narrow nasal cavity jam once more originally, further worsen respiratory tract environment. In addition, compared with the support with the vertical reinforcing ribs, the support with the spiral reinforcing ribs has the advantages that the maximum wall pressure and the maximum deformation of the support under the same stress condition are obviously reduced, and the smooth breathing and the beautiful appearance of a patient after the support is implanted are ensured.
Furthermore, the annealing treatment on the thermoplastic polymer material adopted in the embodiment can release the internal stress of the stent caused during the crimping, improve the bonding strength at the welding seam, and increase the crystallinity of the polymer by controlling the annealing temperature and time parameters, so that the brittleness of the raw material is improved, and the stent has good elasticity and meets the service requirement.
S130, forming a porous drug carrying layer on the surface of the hollow stent, and specifically comprising the following steps:
immersing the hollow stent into 80-120 mL of mixed solution of drug and chitosan, ultrasonically immersing for 0.5-1.5 h, and then carrying out freeze drying treatment to enable the chitosan to crust on the surface of the hollow stent to form a porous drug carrying layer.
The drug of the present embodiment can be selected according to actual needs, and the drug-chitosan mixed solution of the present embodiment includes acetic acid at a concentration ranging from 1% (v/v) to 3% (v/v), chitosan at a viscosity ranging from 400mPa · s to 600mPa · s and at a concentration ranging from 1% (w/v) to 3% (w/v), and sirolimus drug; wherein, the sirolimus drug loading amount accounts for 10% (w/w) to 20% (w/w) of the total amount of the chitosan, namely, the sirolimus drug is loaded in the porous of the chitosan, and the chitosan is encrusted on the surface of the hollow stent to form the porous drug loading.
In the embodiment, the porous drug carrying layer is formed on the hollow stent formed by 3D printing through outer layer dipping and freeze drying, and compared with the traditional direct spraying method, the process increases the binding force between the drug and the stent, so that the drug layer cannot fall off.
S140, hole sealing treatment is carried out on the porous medicine carrying layer to obtain the sinus duct support, and the method specifically comprises the following steps:
immersing the hollow stent with the porous drug carrying layer into 80-120 mL of sodium alginate saturated aqueous solution, and dropwise adding the solution into 80-120 mL of CaCl2Mechanically stirring the solution for 5 to 15min to form calcium alginate hydrogel;
and (3) sealing the porous drug-carrying layer by using calcium alginate hydrogel, and carrying out freeze drying treatment to obtain the sinus duct stent.
In the embodiment, the porous drug carrying layer in the previous step is subjected to hole sealing treatment by adopting the calcium alginate hydrogel, so that the escape of the stent from the matrix and subsequent burst release of the drug are effectively prevented in the deployment process, namely, the drug loss in the conveying process is effectively reduced, the problem of insufficient drug carrying capacity is avoided, and the probability of occurrence of medical accidents such as secondary blockage caused by the fact that the nasal cavity granulation tissue grows into the nasal cavity space is also prevented. The porous structure of the sinus duct stent shell of the embodiment creates a space for the radial elastic expansion of the stent, thereby greatly reducing the probability of stent displacement after the stent is successfully deployed.
The invention aims to improve the efficiency of the prior art, reduce the manufacturing cost of the stent, and prepare the sinus duct stent which is matched with a patient in size, has good toughness, can be completely degraded, and can inhibit granulation tissue hyperplasia and prevent sudden release and falling of the drug. The preparation method solves the problems of limited size and high brittleness of the finished product of the fused deposition type 3D printing technology, effectively avoids the problems of stress concentration, easy falling of a medicine-carrying layer, sudden release of the medicine and the like caused by the existence of a vertical welding line on the bracket, and achieves the purpose of supporting a collapsed nasal cavity and inhibiting the proliferation of granulation tissue from growing into the nasal cavity space.
The method of making the sinonasal stent will be further described with reference to several specific examples below:
example 1
The preparation method of the sinus duct stent in the present example comprises the following steps:
and S1, establishing a support side structure model by using three-dimensional modeling software, exporting a file format of stl file, importing the stl file into a fused deposition type 3D printer, and printing a side unfolding structure sheet model which is provided with patterns and has a parallelogram shape by using polycaprolactone (Mv 40,000, PCL) as a raw material, namely printing the sheet. The specific parameters of the side structure of the parallelogram sheet printed in this embodiment are as follows: the length L is 10.0mm, the width W is 20mm, and the sheet thickness t is 0.1 mm.
S2, coiling the parallelogram slice obtained in the step S1 around a thin copper rod with the diameter of 3.0mm for a circle according to a preset direction (refer to a line 004 in a figure 2), pre-fixing the welded two ends (refer to a line 003 in the figure 2) and the middle part by using thin copper wires, and putting the obtained product into a vacuum drying oven at the temperature of 40 ℃ for primary heat treatment and shaping for 2min to form a semi-finished hollow bracket.
Furthermore, after the obtained semi-finished hollow bracket is taken out, a hot gas welding technology is adopted, hot gas reaching the melting point temperature is used for melting two sides of the degradable polymer parallelogram slice together, and welding pressure is applied to a welding area to achieve the purpose of tight welding. And after the hot gas welding is finished, placing the support accompanied with the fine copper rod support into a vacuum drying oven at 45 ℃ for secondary annealing treatment for 5min, and extracting the copper rod to obtain the hollow support with firm combination.
S3, immersing the stent obtained in the step S2 in 100mL of sirolimus-chitosan mixed solution, ultrasonically soaking for 1h to enable the chitosan to be crusted on the surface of the hollow stent after the solvent is volatilized, and then taking out the hollow stent to be subjected to freeze drying treatment so as to form a porous supporting layer on the surface of the hollow stent. The solution system of the embodiment uses acetic acid as a solvent, the viscosity of the used chitosan is 400 mPas, the concentration of the chitosan solution is 2% (w/v), the solvent acetic acid is a 2% (v/v) aqueous solution, and the sirolimus supporting amount accounts for 10% (w/w) of the total amount of the chitosan.
S4, immersing the hollow stent with the porous drug-carrying layer obtained in the step S3 in 100mL of a saturated aqueous solution of sodium alginate, and adding 100mL of CaCl dropwise with a 21-gauge needle (21-G)2In the solution (1.0%, w/v), the calcium alginate hydrogel was mechanically stirred for 10 minutes to seal the porous layer on the surface of the stent, and then the calcium alginate hydrogel was freeze-dried and stored in a thermostat at 4 ℃ to obtain a sinus duct stent.
Further, since the welding edge of the sinus canal stent formed in the embodiment is spiral, correspondingly, the formed reinforcing rib is also spiral, which has a certain difference from the conventional vertical welding edge. Therefore, the present embodiment further analyzes the simulated force analysis diagram of the sinus canal stent with the vertical welding edge and the spiral welding edge. Specifically, as shown in fig. 5, wherein fig. 5(a) and 5(b) are respectively a stress cloud chart of the stent with vertical welding edges under the simulation of nasal cavity wall pressure; fig. 5(c) and 5(d) are deformation clouds of a stent with a spiral-shaped welded edge under simulation of nasal cavity wall pressure, respectively. As can be known from analog simulation analysis, compared with a vertical reinforcing rib, the support with the spiral welding edge has smaller deformation displacement, the spiral reinforcing rib effectively disperses the pressure and holding force to the periphery of the support wall, and the support with the spiral reinforcing rib has the advantages that the maximum wall pressure and the maximum deformation of the support are obviously reduced under the same stress condition compared with the support with the vertical reinforcing rib.
Further, when the sinotubular stent formed in this embodiment is taken as an example to further analyze scanning electron micrographs, as shown in fig. 6, a loose and porous chitosan shell layer is formed on the surface of the polymer-based stent, wherein larger pores in the chitosan shell layer can be used for carrying drugs and has higher biological safety.
Example 2
The preparation method of the sinus duct stent in the present example comprises the following steps:
s1, building a stent side structure model by using three-dimensional modeling software, exporting a file format of stl file, importing the stl file into a fused deposition 3D printer, and printing a side-unfolded structure sheet model with a pattern and a parallelogram shape, that is, printing a sheet, using polylactic-glycolic acid (Mv: 80,000, PLGA) as a raw material. The specific parameters of the side structure of the parallelogram sheet printed in this embodiment are as follows: the length L is 13.0mm, the width W is 25.0mm, and the sheet thickness t is 0.2 mm.
S2, coiling the parallelogram slice obtained in the step S1 around a thin copper rod with the diameter of 4.0mm for a circle according to a preset direction (refer to a line 004 in a figure 2), pre-fixing the two welded ends (refer to a line 003 in a figure 2) and the middle by using thin copper wires, and putting the fixed copper rod into a vacuum drying oven at the temperature of 45 ℃ for primary heat treatment and shaping for 3min to form a semi-finished hollow bracket.
Furthermore, after the obtained semi-finished hollow bracket is taken out, a hot gas welding technology is adopted, hot gas reaching the melting point temperature is used for melting two sides of the degradable polymer parallelogram slice together, and welding pressure is applied to a welding area to achieve the purpose of tight welding. And after the hot gas welding is finished, placing the support accompanied with the fine copper rod support into a vacuum drying oven at 45 ℃ for secondary annealing treatment for 10min, and extracting the copper rod to obtain the hollow support with firm combination.
S3, immersing the stent obtained in the step S2 in 100mL of sirolimus-chitosan mixed solution for ultrasonic immersion for 1h to allow the solvent to volatilize and then chitosan to be encrusted on the surface of the stent, and then taking out the stent for freeze drying treatment to form a porous supporting layer on the surface of the hollow stent. The solution system of the embodiment uses acetic acid as a solvent, the viscosity of the used chitosan is 500 mPas, the concentration of the chitosan solution is 2% (w/v), the solvent acetic acid is a 2% (v/v) aqueous solution, and the sirolimus supporting amount accounts for 10% (w/w) of the total amount of the chitosan.
S4, immersing the hollow stent with the porous drug-carrying layer obtained in the step S3 in 100mL of a saturated aqueous solution of sodium alginate, and adding 100mL of CaCl dropwise with a 21-gauge needle (21-G)2In the solution (1.0%, w/v), the calcium alginate hydrogel was mechanically stirred for 10 minutes to seal the porous layer on the surface of the stent, and then the calcium alginate hydrogel was freeze-dried and stored in a thermostat at 4 ℃ to obtain a sinus duct stent.
Example 3
The preparation method of the sinus duct stent in the present example comprises the following steps:
s1, building a stent side structure model using three-dimensional modeling software, exporting a file format of stl file, importing the stl file into a fused deposition 3D printer, and printing a side unfolded structure sheet model having a pattern and a parallelogram shape using polylactic-glycolic acid (Mv: 100,000, PLGA) as a raw material. I.e. a sheet is printed out. The specific parameters of the side structure of the parallelogram sheet printed in this embodiment are as follows: the length L is 16.0mm, the width W is 30.0mm, and the sheet thickness t is 0.3 mm.
S2, curling the parallelogram slice obtained in the step S1 around a thin copper rod with the diameter of 5.0mm for a circle according to a preset direction (refer to a line 004 in a figure 2), pre-fixing the two welded ends (refer to a line 003 in a figure 2) and the middle by using thin copper wires, and putting the parallelogram slice into a vacuum drying oven at the temperature of 45 ℃ for primary heat treatment and shaping for 5min to form a semi-finished hollow bracket.
Furthermore, after the obtained hollow bracket semi-finished product is taken out, a hot gas welding technology is adopted, hot gas reaching the melting point temperature is used for melting two sides of the degradable polymer parallelogram slice together, and welding pressure is applied to a welding area to achieve the purpose of tight welding. And after the hot gas welding is finished, placing the support accompanied with the fine copper rod support into a vacuum drying oven at 45 ℃ for secondary annealing treatment for 15min, and extracting the copper rod to obtain the hollow support with firm combination.
S3, immersing the stent obtained in the step S2 in 100mL of sirolimus-chitosan mixed solution, ultrasonically soaking for 1h to enable the chitosan to be crusted on the surface of the stent after the solvent is volatilized, and then taking out the stent to be subjected to freeze drying treatment so as to form a porous supporting layer on the surface of the hollow stent. The solution system of the embodiment uses acetic acid as a solvent, the viscosity of the used chitosan is 600 mPas, the concentration of the chitosan solution is 2% (w/v), the solvent acetic acid is a 2% (v/v) aqueous solution, and the sirolimus supporting amount accounts for 10% (w/w) of the total amount of the chitosan.
S4, immersing the hollow stent with the porous drug-carrying layer obtained in the step S3 in 100mL of a saturated aqueous solution of sodium alginate, and adding 100mL of CaCl dropwise with a 21-gauge needle (21-G)2In the solution (1.0%, w/v), the calcium alginate hydrogel was mechanically stirred for 10 minutes to seal the porous layer on the surface of the stent, and then the calcium alginate hydrogel was freeze-dried and stored in a thermostat at 4 ℃ to obtain a sinus duct stent.
Example 4
The preparation method of the sinus duct stent in the present example comprises the following steps:
s1, building a stent side structure model using three-dimensional modeling software, exporting a file format of stl file, importing the stl file into a fused deposition 3D printer, and printing a side unfolded structure sheet model having a pattern and a parallelogram shape using polylactic-glycolic acid (Mv-200,000, PLGA) as a raw material. I.e. a sheet is printed out. The specific parameters of the side structure of the parallelogram sheet printed in this embodiment are as follows: the length L is 19.0mm, the width W is 30.0mm, and the sheet thickness t is 0.5 mm.
S2, coiling the parallelogram slice obtained in the step S1 around a thin copper rod with the diameter of 6.0mm for a circle according to a preset direction (refer to a line 004 in a figure 2), pre-fixing the welded two ends (refer to a line 003 in the figure 2) and the middle part by using thin copper wires, and putting the obtained product into a vacuum drying oven at the temperature of 50 ℃ for primary heat treatment and shaping for 5min to form a semi-finished hollow bracket.
Furthermore, after the obtained hollow bracket semi-finished product is taken out, a hot gas welding technology is adopted, hot gas reaching the melting point temperature is used for melting two sides of the degradable polymer parallelogram slice together, and welding pressure is applied to a welding area to achieve the purpose of tight welding. And after the hot gas welding is finished, placing the bracket accompanied with the fine copper rod support into a vacuum drying oven at 50 ℃ for secondary annealing treatment for 20min, and extracting the copper rod to obtain the firmly-combined hollow bracket.
S3, immersing the stent obtained in the step S2 in 100mL of sirolimus-chitosan mixed solution, ultrasonically soaking for 1h to enable the chitosan to be crusted on the surface of the stent after the solvent is volatilized, and then taking out the stent to be subjected to freeze drying treatment so as to form a porous supporting layer on the surface of the hollow stent. The solution system of the embodiment uses acetic acid as a solvent, the viscosity of the used chitosan is 600 mPas, the concentration of the chitosan solution is 2% (w/v), the solvent acetic acid is a 2% (v/v) aqueous solution, and the sirolimus supporting amount accounts for 10% (w/w) of the total amount of the chitosan.
S4, immersing the hollow stent with the porous drug-carrying layer obtained in the step S3 in 100mL of a saturated aqueous solution of sodium alginate, and adding 100mL of CaCl dropwise with a 21-gauge needle (21-G)2In the solution (1.0%, w/v), the calcium alginate hydrogel was mechanically stirred for 10 minutes to seal the porous layer on the surface of the stent, and then the calcium alginate hydrogel was freeze-dried and stored in a thermostat at 4 ℃ to obtain a sinus duct stent.
Further, the sinus tube stent formed in this example and having an inner diameter of 6mm was further analyzed for the compression-rebound curve of the radial deformation rate of 50% for the sinus tube stents having wall thicknesses of 0.1mm, 0.3mm and 0.5mm, as shown in fig. 7, it can be seen that the supporting ability is increased with the increase of the wall thickness of the stent, but the rebound rate after contraction is decreased. Therefore, the sinus duct stent of the embodiment can achieve the purpose of balancing the support force and the rebound rate of the stent by designing the thickness of the stent during three-dimensional modeling. That is, the thickness of the design support, that is, the thickness of the 3D printing sheet, can be specifically set according to actual needs in the present embodiment.
As shown in fig. 4, in a second aspect of the present invention, a sinus duct support is provided, which is a cylindrical hollow support, and is prepared by the above-mentioned method for preparing a sinus duct support, and the specific preparation method is referred to the above-mentioned description and will not be described herein again.
This sinus pipe support possesses thermotropic shape memory deformability, can take place to correspondingly accomplish shrink and from the expansion action under the temperature stimulation, and based on this characteristics, this embodiment adopts thermotropic excitation recovery method to deploy the sinus pipe support, and concrete step includes:
and carrying out gamma ray disinfection and sterilization treatment on the obtained sinus tube stent, namely, putting the sinus tube stent in a constant temperature water bath system at 40-45 ℃, enabling the diameter to be shrunk under a sinus tube stent compression tool, conveying the sinus tube stent to a collapsed nasal cavity through a sinus tube stent catheter, wherein the compression time in the water bath system is controlled within 30s, and then washing the sinus tube stent for 8-12 s under the heat flow of 35-40 ℃, thus finishing the deployment of the sinus tube stent.
The specific deployment method of the sinus duct support will be further described with reference to several specific examples:
example 5
The sinus tube stent obtained in example 1 described above was subjected to gamma ray sterilization treatment. After that, the sterilized sinus canal stent is placed in a constant temperature water bath system at 40 ℃, and the diameter is contracted under a stent crimping tool and is conveyed to the collapsed nasal cavity through a stent catheter, wherein the crimping time in the water bath system is controlled within 30s, and the sinus canal stent is flushed for 10s under the heat flow of 35 ℃, so that the deployment of the sinus canal stent in the example can be completed.
Example 6
The sinus tube stent obtained in example 2 described above was subjected to gamma ray sterilization treatment. The sterilized sinus tube stent is then placed in a constant temperature water bath system at 42 ℃ and is compressed in diameter under a stent crimping tool and delivered to the collapsed nasal cavity through a stent catheter, wherein the crimping time in the water bath system is controlled within 30 seconds, and the sinus tube stent is rinsed for 10 seconds under 38 ℃ heat flow, thus completing the deployment of the sinus tube stent in the present example.
Example 7
The sinus tube stent obtained in example 3 described above was subjected to gamma ray sterilization treatment. After that, the sterilized sinus canal stent is placed in a constant temperature water bath system at 45 ℃ and is subjected to diameter shrinkage under a stent crimping tool and is conveyed to the collapsed nasal cavity through a stent catheter, wherein the crimping time in the water bath system is controlled within 30s, and the sinus canal stent is rinsed for 10s under the heat flow of 38 ℃, so that the deployment of the sinus canal stent in the example can be completed.
Example 8
The sinus tube stent obtained in example 4 described above was subjected to gamma ray sterilization treatment. After that, the sterilized sinus canal stent is placed in a constant temperature water bath system at 45 ℃ and is subjected to diameter shrinkage under a stent crimping tool and is conveyed to the collapsed nasal cavity through a stent catheter, wherein the crimping time in the water bath system is controlled within 30s, and the sinus canal stent is rinsed for 10s under heat flow at 40 ℃, so that the deployment of the sinus canal stent in the example can be completed.
It should be noted that, the deployment of the sinus duct stent in the present embodiment corresponds to the 4 embodiments described above, and it is obvious to those skilled in the art that the specific deployment may be performed according to actual situations, that is, the temperature and time involved in the deployment of the sinus duct stent may be set according to actual situations, which is not particularly limited.
Compared with a traditional sacculus expansion support recovery system, the support thermotropic excitation recovery method adopted by the prepared paranasal sinus tube support makes full use of the shape memory recovery function of the support framework, greatly reduces the risk of mechanical scraping and even wall breaking caused by the sacculus to the nasal cavity when the support is mechanically expanded, creates a space for radial elastic expansion of the support due to the porous structure of the paranasal sinus tube support shell, and greatly reduces the probability of support displacement after the support is successfully deployed. In addition, after the drug on the surface of the sinus duct stent prepared by the embodiment is released, the completely degradable stent main body can be automatically degraded into fragments to enter a human body excretion system, the remains of the stent are taken out without a secondary operation, the biological safety is higher, the pain and the burden of a patient are reduced, and the stent implanted into the nasal cavity which is collapsed in the day can achieve the effect of gradually healing while the respiratory capacity of the patient is improved.
The invention provides a sinus duct stent and a preparation method thereof, and compared with the prior art, the sinus duct stent has the following beneficial effects: firstly, the invention adopts a 3D printing rapid forming technology, is not limited by the precision of a fused deposition type 3D printer instrument, ensures the consistency of forming conditions of each part of the bracket, so that the bracket has good elasticity, and the 3D printing prefabricated bracket side surface unfolding structure is combined with a hot gas welding technology, so that the brackets with different diameters and wall thickness ranges can be prepared to meet the requirements of different patient individuals on the size, radial supporting force, elasticity and compliance of the bracket, and the radial supporting force and the rebound rate of the bracket can be adjusted through the wall thickness of the bracket. Secondly, the spiral reinforcing ribs formed on the bracket by utilizing the hot gas welding technology ensure the radial elasticity of the bracket, ensure that the bracket cannot be broken and lose efficacy early when being pressed by the nasal cavity wall, and effectively prevent the bracket part at the broken part from causing larger block falling off to cause the blockage of the original narrow nasal cavity again. Compared with a vertical reinforcing rib, the spiral reinforcing rib effectively disperses the compression and holding force applied to the periphery of the wall of the support, and the support with the spiral reinforcing rib has the advantages that the maximum wall pressure and the maximum deformation of the support are obviously reduced under the same stress condition compared with the support with the vertical reinforcing rib. Thirdly, the invention adopts the annealing treatment to the thermoplastic polymer material to release the internal stress of the bracket caused during the curling, simultaneously improves the bonding strength of the welding seam, and simultaneously can increase the crystallinity of the polymer by controlling the annealing temperature and time parameters, so that the brittleness of the raw material is improved, and the bracket has good elasticity and meets the service requirement. And the porous drug-carrying layer is formed, so that the binding force between the drug and the stent is increased compared with a direct spraying method, the drug layer cannot fall off, the porous drug-carrying layer is subjected to hole sealing treatment by adopting calcium alginate hydrogel, the stent is effectively prevented from escaping from a matrix and subsequent burst release of the drug in the deployment process, the problem of insufficient drug-carrying capacity is avoided, and the probability of occurrence of medical accidents such as secondary blockage caused by the fact that the nasal cavity granulation tissue grows into the nasal cavity space is prevented. Compared with a balloon-expandable stent recovery system, the stent thermotropic excitation recovery method fully utilizes the shape memory recovery function of the stent framework, greatly reduces the risk of mechanical scraping and even wall breaking of the nasal cavity caused by the balloon during mechanical stent expansion, and greatly reduces the probability of stent displacement after the stent is successfully deployed because the porous structure of the sinus canal stent shell creates space for radial elastic expansion of the stent. Sixth, after the drug on the surface of the sinus duct stent is released, the completely degradable stent main body can be automatically degraded into fragments to enter a human body excretion system, the remains of the stent do not need to be taken out in a secondary operation, the pain and the burden of a patient are reduced, and the stent is implanted into a nasal cavity which is collapsed in nature, so that the respiratory capacity of the patient can be increased, and the effect of gradual healing can be achieved.
It will be understood that the above embodiments are merely exemplary embodiments taken to illustrate the principles of the present invention, which is not limited thereto. It will be apparent to those skilled in the art that various modifications and improvements can be made without departing from the spirit and substance of the invention, and these modifications and improvements are also considered to be within the scope of the invention.

Claims (10)

1. A preparation method of a sinus duct stent is characterized by comprising the following specific steps:
providing a preset thermoplastic degradable polymer, and printing the thermoplastic degradable polymer into a thin sheet on an XOY plane by adopting a 3D printing technology;
coiling the thin slice around a preset reference shaft to form an annular structure, and after the thin slice is pre-fixed, carrying out heat treatment setting on the annular structure to obtain a hollow support;
forming a porous drug-carrying layer on the surface of the hollow stent;
and carrying out hole sealing treatment on the porous medicine carrying layer to obtain the sinus duct stent.
2. The method of claim 1, wherein the pre-fixing is followed by heat setting the loop structure to obtain a hollow stent, comprising:
carrying out heat treatment setting on the annular structure at 40-50 ℃ for 2-5 min to obtain a semi-finished hollow bracket;
and preparing and forming a reinforcing rib on the semi-finished hollow support to obtain the hollow support.
3. The method for preparing a sinus tube support according to claim 2, wherein the preparing and forming of the reinforcing rib on the semi-finished hollow support to obtain the hollow support comprises:
and melting the welding areas on the two sides of the semi-finished hollow support, applying welding pressure to form a spiral reinforcing rib wound on the outer surface of the semi-finished hollow support, and annealing at 40-50 ℃ for 5-20 min to obtain the hollow support.
4. The method of preparing a sinus tube support according to any one of claims 1 to 3, wherein the forming a porous drug-carrying layer on the surface of the hollow support comprises:
immersing the hollow stent into 80-120 mL of mixed solution of drug and chitosan, ultrasonically immersing for 0.5-1.5 h, and then carrying out freeze drying treatment to enable the chitosan to crust on the surface of the hollow stent to form the porous drug carrying layer.
5. The method for preparing a sinus tube stent according to claim 4, wherein the drug-chitosan mixed solution comprises acetic acid at a concentration ranging from 1% (v/v) to 3% (v/v), chitosan at a viscosity ranging from 400 mPa-s to 600 mPa-s at a concentration ranging from 1% (w/v) to 3% (w/v), and sirolimus drug; wherein the content of the first and second substances,
the sirolimus drug loading amount accounts for 10% (w/w) to 20% (w/w) of the total amount of the chitosan.
6. The method for preparing a sinus tube support according to any one of claims 1 to 3, wherein the sealing the porous drug-carrying layer to obtain the sinus tube support comprises:
immersing the hollow stent with the porous drug-carrying layer into 80-120 mL of sodium alginate saturated aqueous solution, and dropwise adding the solution into 80-120 mL of CaCl2Mechanically stirring the solution for 5 to 15min to form calcium alginate hydrogel;
and sealing the porous drug-carrying layer by using the calcium alginate hydrogel, and carrying out freeze drying treatment to obtain the sinus duct stent.
7. The method of preparing a sinus tube stent according to any one of claims 1 to 3, wherein the thermoplastic degradable polymer comprises at least one of polylactic acid, polycaprolactone, polyglycolic acid, polylactic-glycolic acid.
8. The method of preparing a sinus tube support according to any one of claims 1 to 3, wherein the sheet is a parallelogram-shaped sheet; wherein the content of the first and second substances,
the parallelogram thin slice is provided with any one of rhombus patterns, triangle patterns, trapezoid patterns and circular patterns which penetrate through the thickness of the parallelogram thin slice.
9. A method of preparing a sinus tube stent according to any one of claims 1 to 3, wherein the sheet has a length in the range of 10mm to 20mm, a width in the range of 20mm to 30mm, and a thickness in the range of 0.1mm to 0.5 mm.
10. A sinus duct stent prepared by the method of preparing a sinus duct stent according to any one of claims 1 to 9.
CN202010353321.5A 2020-04-28 2020-04-28 Sinus duct stent and preparation method thereof Active CN111529150B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202010353321.5A CN111529150B (en) 2020-04-28 2020-04-28 Sinus duct stent and preparation method thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202010353321.5A CN111529150B (en) 2020-04-28 2020-04-28 Sinus duct stent and preparation method thereof

Publications (2)

Publication Number Publication Date
CN111529150A true CN111529150A (en) 2020-08-14
CN111529150B CN111529150B (en) 2023-02-24

Family

ID=71973204

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202010353321.5A Active CN111529150B (en) 2020-04-28 2020-04-28 Sinus duct stent and preparation method thereof

Country Status (1)

Country Link
CN (1) CN111529150B (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112932737A (en) * 2021-03-19 2021-06-11 常州大学 Drug-loaded degradable 3D printing sinus stent and preparation method thereof
CN114403968A (en) * 2021-12-30 2022-04-29 杭州唯强医疗科技有限公司 Intracavity occluder and processing method thereof
CN115317675A (en) * 2022-08-23 2022-11-11 苏州中天医疗器械科技有限公司 Drug eluting stent and preparation method and application thereof

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1557507A (en) * 2004-01-16 2004-12-29 东南大学 Re-stricture preventing medicinal sustained releasing bracket and its preparation
US20050021128A1 (en) * 2003-07-24 2005-01-27 Medtronic Vascular, Inc. Compliant, porous, rolled stent
CN101437471A (en) * 2006-04-12 2009-05-20 动脉再造技术股份有限公司 Methods of polymeric stent surface smoothing and resurfacing to reduce biologically active sites
CN101879102A (en) * 2009-05-07 2010-11-10 微创医疗器械(上海)有限公司 Groove carrying-type coating decomposable drug eluting stent
CN108606861A (en) * 2018-05-07 2018-10-02 哈尔滨工业大学 A kind of imitative glass sponge holder and preparation method thereof
CN110115651A (en) * 2019-05-15 2019-08-13 四川兴泰普乐医疗科技有限公司 A kind of 3D printing bracket with drug slow release function
CN110226994A (en) * 2018-03-06 2019-09-13 江苏启灏医疗科技有限公司 A kind of nasal cavity bracket and preparation method thereof

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050021128A1 (en) * 2003-07-24 2005-01-27 Medtronic Vascular, Inc. Compliant, porous, rolled stent
CN1557507A (en) * 2004-01-16 2004-12-29 东南大学 Re-stricture preventing medicinal sustained releasing bracket and its preparation
CN101437471A (en) * 2006-04-12 2009-05-20 动脉再造技术股份有限公司 Methods of polymeric stent surface smoothing and resurfacing to reduce biologically active sites
CN101879102A (en) * 2009-05-07 2010-11-10 微创医疗器械(上海)有限公司 Groove carrying-type coating decomposable drug eluting stent
CN110226994A (en) * 2018-03-06 2019-09-13 江苏启灏医疗科技有限公司 A kind of nasal cavity bracket and preparation method thereof
CN108606861A (en) * 2018-05-07 2018-10-02 哈尔滨工业大学 A kind of imitative glass sponge holder and preparation method thereof
CN110115651A (en) * 2019-05-15 2019-08-13 四川兴泰普乐医疗科技有限公司 A kind of 3D printing bracket with drug slow release function

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112932737A (en) * 2021-03-19 2021-06-11 常州大学 Drug-loaded degradable 3D printing sinus stent and preparation method thereof
CN112932737B (en) * 2021-03-19 2022-07-19 常州大学 Drug-loaded degradable 3D printing sinus stent and preparation method thereof
CN114403968A (en) * 2021-12-30 2022-04-29 杭州唯强医疗科技有限公司 Intracavity occluder and processing method thereof
CN114403968B (en) * 2021-12-30 2023-11-14 杭州唯强医疗科技有限公司 Intracavity occluder and processing method thereof
CN115317675A (en) * 2022-08-23 2022-11-11 苏州中天医疗器械科技有限公司 Drug eluting stent and preparation method and application thereof
CN115317675B (en) * 2022-08-23 2024-02-27 苏州中天医疗器械科技有限公司 Drug eluting stent and preparation method and application thereof

Also Published As

Publication number Publication date
CN111529150B (en) 2023-02-24

Similar Documents

Publication Publication Date Title
CN111529150B (en) Sinus duct stent and preparation method thereof
US9833344B2 (en) Stent made from an ultra high molecular weight bioabsorbable polymer with high fatigue and fracture resistance
JP4500975B2 (en) Intravascular implant for applying an agent and method of manufacturing a microdevice for injecting an agent
US9855131B2 (en) Vascular grafts with multiple channels and methods for making
KR102035878B1 (en) Eluting medical devices
US9833342B2 (en) Tracheobronchial implantable medical device and methods of use
EP2833844B1 (en) Control of balloon inflation rate during deployment of scaffold
US20180229426A1 (en) Stent
JP2005515021A (en) Struts with stent bumpers
WO2004022150A1 (en) Stent and process for producing the same
CN104870028A (en) Fully absorbable intraluminal devices and methods of manufacturing the same
CN109688983A (en) Medicine released biological degradability bracket
EP2563287B1 (en) Drug eluting folded stent and stent delivery system
CN111759552A (en) Absorbable stent system
JP3358048B2 (en) Shell for prosthesis and method for producing the same
CN213030946U (en) Degradable drug stent delivery system
Ivone et al. Recent advances in 3D printing for parenteral applications
US20150051686A1 (en) Bioresorbable scaffold for treatment of bifurcation lesion
CN106955175A (en) Medical rack
KR102221074B1 (en) A stent comprising biodegradable polymer and nitinol and method for preparing thereof
CN208552143U (en) A kind of endovascular stent and product
CN107693176A (en) The intranasal support of balloon-expandable
CN111760179A (en) External vascular stent and application thereof
CN208287108U (en) Medical rack
CN202859730U (en) Elasticity shape memory recyclable bracket

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant